Clinical trial NCT01628653: Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training
Official title: Feasibility and Efficacy of the Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training (U-SMART) on Mild Cognitive Impairment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Mild Cognitive Impairment
Keywords: Mild cognitive impairment
Cognitive rehabilitation
Cognitive therapy
Spaced retrieval Training
Alzheimer's disease
Memory enhancement
U-healthcare
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
Collaborators: name: KT Corporation
First posted: 2012-06-27
Enrollment: 10
Sex: ALL
Minimum age (years): 55
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine feasibility and efficacy of the Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training (U-SMART) in the elderly individuals with mild cognitive impairment (MCI).

Detailed description: The Spaced Retrieval-based Memory Advancement and Rehabilitation Training (SMART) which consisted of 24 one-hour face-to-face sessions (Lee, Park et al. 2009) was developed based on the spaced retrieval training (SRT), which was effective in improving memory retention span of very mild to mild Alzheimer's disease patients. The Ubiquitous SMART (U-SMART) by transforming the current SMART to a self-administered program using an application working on IPAD was developed, and was examined its feasibility and efficacy in the elderly individuals with mild cognitive impairment.

Eligibility criteria: Inclusion Criteria:

* Aged 55-90
* Educational level above 1 year and confirmed literacy
* Diagnosed to mild cognitive impairment by International Working Group on Mild Cognitive Impairment
* Clinical Dementia Rating (CDR) of 0 or 0.5

Exclusion Criteria:

* Diagnosed to dementia by DSM-IV
* Evidence of delirium, confusion
* Any neurological conditions causing cognitive decline such as Parkinson's disease, brain hemorrhage, brain tumor, normal pressure hydrocephalus
* Evidence of severe cerebrovascular pathology
* History of loss-of-consciousness over 1 hour due to head trauma or repetitive head trauma of mild severity
* History of substance abuse or dependence such as alcohol
* Presence of depressive symptoms that could influence cognitive function
* Presence of medical comorbidities that could result in cognitive decline
* Use of medication that could influence cognitive function seriously

Primary outcomes:
measure: the five-point Likert scales for satisfaction and compliance
timeFrame: after 4-weeks treatment
measure: Word List Memory Test of the CERAD Neuropsychological Assessment Battery
timeFrame: after 4-weeks treatment
Secondary outcomes:
measure: Mini-Mental State Examination (MMSE)
timeFrame: after 4-weeks treatment
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi
Study officials:
affiliation: Seoul National University Bundang Hospital, Seong-nam, Korea
name: Ki Woong Kim, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: